It appears that Enliven Therapeutics’ decision to pivot away from a solid tumor drug now seems like a wise one.
Enliven said on Thursday that its tyrosine kinase …
Read More from Endpoints News
Enliven’s Phase 1 leukemia pill data look competitive with Novartis and Terns
